Found 16 Acute Myeloid Leukemia trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 49422: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

99 years and younger

All genders

Please refer to Protocol, Section 2.0 (Objectives) Please refer to Protocol, Section 4.0 (Study Endpoints) Please refer to Protocol, Section 4.0 (Study Endpoints)

Learn More

UPCC 43423: A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

99 years and younger

All genders

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML. We would like to rely on Advarra IRB as the IRB …

Learn More

UPCC 35424 TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

99 years and younger

All genders

Please refer to Protocol Section 2.1 (Objectives). Please refer to Protocol Section 2.2.1 (Primary Endpoints). Please refer to Protocol Section 2.2.2 (Secondary Endpoints).

Learn More

UPCC 23423: Full Protocol Title A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination with the FLT3 Inhibitor Gilteritinib, in Patients with FLT

99 years and younger

All genders

This study tests an investigational drug called LANRA as a possible treatment for people with relapsed or refractory FLT3-mutated AML. This study will take place in 2 parts. In Part 1 (dose escalation), the main purpose is to determine the maximal dose of LANRA that can be safely administered and …

Learn More

UPCC 26423 Phase 1 Study of Lentivirally Transduced T Cells Engineered to Contain Anti-CD33 Linked to TCR and 4-1BB Signaling Domains in Combination with CD33KO-HSPC in Subjects with Refractory or Relapsed Acute Myeloid Leukemia

99 years and younger

All genders

Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints). Please refer to Protocol Section 3.2 (Study Objectives and Endpoints).

Learn More

UPCC 29424 Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase 1 (Ph1) Study of SNDX-5613 + Gilteritinib

99 years and younger

All genders

Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2.1 (Primary Endpoints). Please refer to Protocol Section 2.2 (Secondary Endpoints)

Learn More

11 - 16 of 16